8 Result(s)
within
Andrés Felipe Cardona
-
Article
Open AccessKRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
KRAS-mutant non-small cell lung cancer (NSCLC) shows a relatively low response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors, leading to short median progression-free survival, and overal...
-
Article
Open AccessGenomic ancestry and cancer among Latin Americans
Latin American populations, characterized by intricate admixture patterns resulting from the intermingling of ancestries from European, Native American (NA) Asian, and African ancestries which result in a vast...
-
Article
Open AccessAuthor Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
-
Article
Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data
Treatment-refractory meningiomas have a dismal prognosis and limited treatment options. Meningiomas express high-densities of somatostatin receptors (SSTR), thus potentially susceptible to antitumorigenic eff...
-
Article
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are a frequent class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial clinical benefit, but almost ...
-
Article
Open AccessAURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
Non-small cell lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs). Here, we show that resistant cells without the p.T790M or othe...
-
Article
Open AccessBIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expressio...
-
Article
Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients
Methylation of the promoter of the MGMT gene and MGMT protein expression are recognized as predictive markers for response to alkylating chemotherapy in glioblastoma (GB).
